EMERYVILLE, Calif.--(BUSINESS WIRE)--April 21, 2026-- 

OmniAb, Inc. $(OABI)$ will report financial results for the three months ended March 31, 2026, after the close of the U.S. financial markets on Thursday, May 7, 2026, and will hold a conference call that same day beginning at 4:30 p.m. Eastern time.

Conference Call and Webcast Information

 
What:       OmniAb conference call to discuss first quarter 2026 financial 
            results and business updates 
 
Date:       Thursday, May 7, 2026 
 
Time:       4:30 p.m. Eastern time (1:30 p.m. Pacific time) 
 
Phone:      U.S. (833) 461-5787 
            International (585) 542-9983 
            Conference ID is 563758100 
 
Webcast:    Live and replay webcast of the call with slides will be available 
            here. 
 

About OmniAb$(R)$

OmniAb licenses cutting-edge discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of next-generation therapeutics. Our technology platform creates and screens diverse antibody repertoires and is designed to quickly identify optimal antibodies and other target-binding proteins for our partners' drug development efforts. At the heart of the OmniAb platform is what we call Biological Intelligence$(TM)$, which powers the immune systems of our proprietary, engineered transgenic animals to create optimized antibody candidates for human therapeutics. We believe the OmniAb animals comprise the most diverse host systems available in the industry. Our suite of technologies and methods, including computational antigen design and immunization methods, paired with high-throughput single B-cell phenotypic screening and mining of next-generation sequencing datasets with custom algorithms, are used to identify fully-human antibodies with exceptional performance and developability characteristics. We provide our partners both integrated end-to-end capabilities and highly customizable offerings, which address critical industry challenges and provide optimized discovery solutions. Our business model aligns scientific and economic interests of our partners through structured agreements that generally include upfront/access fees, service revenue, milestones and royalties on commercial sales.

For more information, please visit www.omniab.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260421375521/en/

 
    CONTACT:    OmniAb, Inc. 

investors@OmniAb.com

X @OmniAbTech

Alliance Advisors IR

Yvonne Briggs

ybriggs@allianceadvisors.com

(310) 691-7100

(END) Dow Jones Newswires

April 21, 2026 08:03 ET (12:03 GMT)